Phylogica Limited (ASX:PYC) announces Cre Enzyme Delivery Provides Validation & Strategic Value
PERTH, Australia, 2 March 2018: Phylogica Limited (ASX:PYC) (Phylogica or the Company), developer of a unique platform to deliver drugs into cells, has delivered new proof of concept cargo, Cre, a well validated recombination enzyme routinely used in biological research.
The proof-of-concept delivery of Cre is an important step in establishing an in vivo system to determine where in the body a drug cargo goes with Phylogica’s FPP delivery technology. The Cre system induces a colour change in cells and organs (e.g. green to red) upon successful delivery of the functional Cre enzyme.
For further information please download PDF attached:
Download this document
